Grace Therapeutics, Inc.
GTx-102
Ataxia-Telangiectasia
Resolved
1297days ago
Phase 2 readout · Dec 18, 2022
What's at stake
Phase 2 trial results for GTx-102 in Ataxia-Telangiectasia are due Dec 18, 2022. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“PK bridging study topline results announced on 12/18/22 met all outcome measures”